AIDS Therapy

ACTG Clinical Trial: Remune alone stimulated stronger immune responses

Published in AIDS Weekly, September 9th, 2002

The Immune Response Corp. (IMNR) announced that the Adult AIDS Clinical Trials Group of the National Institutes of Health presented new data at the XIV International AIDS Conference from a clinical trial designed to ascertain if the nonspecific cytokine, interleuken 2 (IL-2) can enhance immune responses after vaccination with Remune and non-HIV immunizations.

The results suggested that more patients who received Remune while on antiviral drug therapy (HAART) developed stronger immune responses to the HIV (70% vs. 24%, p=0.049) compared with those who received Remune plus IL-2 while on HAART. Similarly, those on HAART alone developed stronger hepatitis A antibodies (88%...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2002-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry